On April 28, 2021, Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, announced the closing of an oversubscribed $105 Million Series B financing. RA Capital Management and Nextech Invest co-led the financing, with participation from a top-tier syndicate of funds, including Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, and Logos Capital. Current investors ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital of Tavistock Group, and Alexandria Venture Investments also participated in the Series B. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHO™) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.

A Wilson Sonsini Goodrich & Rosati team that was led by Deborah Smith and included Céline Bonnefous, Alicia Umpierre, Jennifer Floyd, Erin Boyle Anderson, and Mike Hostetler advised Boundless Bio on IP matters related to the transaction. Additionally, John Slafsky supported the team in trademark matters.

For more information, please see Boundless Bio's press release.